AURIGA INTERN (D)
Identification
AURIGA INTERNATIONAL is a Belgian company active in dermatology research with applications in the medical and aesthetic plastic surgery. It develops and markets innovative products in this sector based on the latest discoveries in biotechnology.
The company also carries out in close collaboration with Belgian universities, targeted research to develop patentable products for various skin treatments.
The range of AURIGA INTERNATIONAL currently extends to 21 products and different brands, distributed in some fifty countries. Research conducted by the company focuses on the development of products addressing the following conditions:
- Treatment of stretch;
- Filling wrinkles;
- Rejuvenation of the face;
- Depigmentation of skin;
- Rings and "pockets" around the eyes;
- Cellulite and liposuction complements;
- Post-operative aesthetic treatment of body and face.
The targeted market segment is that of the medical cosmetic products sold in pharmacies.
Operation
Fixed-Price Offer
Conditions of the fixed-price offer (Fixing by Euronext Brussels) - Fixed-price: 5,76 euros - A maximum of 138.889 shares made available to the market. Result of the fixed-price offer The result of the offer shall be published in a notice in the official price list specifying the conditions in which the trading (first cotation) shall be pursued, subject to the realisation of the increase of capital and the delivery of the certificate by the depositary. Request for listing - Euronext Brussels received an application for listing on the Free Market of Euronext Brussels of maximum 1,388,889 AURIGA INTERNATIONAL ordinary shares representing all of the existing shares of the company. - Euronext Brussels also received an application for listing on the Free Market of Euronext Brussels of maximum 62,500 new ordinary shares, which could be issued following the exercise of 62,500 warrants granted to the staff and issued following the decision of the company AURIGA INTERNATIONAL during the EGM of 12 December 2008.
The shares offered in this public offering results from a public subscription offer of a maximum of 138.889 new shares. The increase in capital giving rise to the issue of shares, which are the object of the public offer, was approved by the EGM on 12 December 2008 under the suspensive condition of the actual subscription of the new shares.
- Date of approval of the prospectus by the CBFA: 09/12/2008 - Opening of the Offer: 05/01/2009 - Closing of the Offer: 25/03/2009 - Fixing date on Euronext: 25/03/2009 (5:15 pm) - Payment date: 30/03/2009 - Settlement-delivery date: 30/03/2009 - First trading date: 01/04/2009
SMALL CAPS FINANCE